Ireland
--:--IST
Latest
Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns Project Management Failures: Lessons for Healthcare FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli WeBuild Programme: 50+ Women-Led Ventures and How to Apply Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Michigan
Clinical trial register · United States · industry-sponsored

Clinical Trials in Michigan, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9122 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 07 Oct 2026, 03:16 UTC
9122
Studies in scope
industry-sponsored, all four open statuses
4946
Recruiting now
open to new participants
2190
Lead sponsors
across recruiting studies
Top states
Texas 87 California 67 Florida 57 New York 50 Michigan 43
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.3 Daiichi Sankyo3 OncoC4, Inc.2 BioNTech SE2 Coherus Oncology, Inc.2
State
Texas87 California67 Florida57 New York50 Michigan43
All 42 states
Target enrolment
to

Trials with a site in Michigan

43 of 9122 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Blueprint Medicines Corporation
Phase 1/2
265
Florida, Louisiana, Massachusetts, Michigan, New Jersey, New York, Tennessee, Texas
2026-06-04
Recruiting
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
NCT07213830Advanced Solid Tumor, Metastatic Solid Tumor
Ipsen
Phase 1/2
102
Michigan, Tennessee, Texas
2026-02-06
Recruiting
A Study of YL242 in Subjects With Advanced Solid Tumors
NCT07197827Advanced Solid Tumor
DrugsAdrucil·Pembrolizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas
2025-09-22
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
DrugsBNT326·Paroxetine·Itraconazole·Pumitamig
BioNTech SE
Phase 1/2
1,438
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Michigan, New York
2025-08-12
Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
DrugIrinotecan
MOMA Therapeutics
Phase 1
132
Arizona, California, Florida, Michigan, Missouri, North Carolina, Oregon, Texas
2025-07-16
Recruiting
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762Advanced Solid Tumor
DrugBevacizumab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Arizona, California, Connecticut, Kansas, Michigan, New York, North Carolina, Ohio
2025-07-02
Recruiting
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
NCT06657144Metastatic Solid Tumor, Advanced Solid Tumor
DrugsCHS-114·Adrucil·Toripalimab·Cisplatin
Coherus Oncology, Inc.
Phase 1
154
Arizona, California, Colorado, Georgia, Louisiana, Michigan, Nevada, New Mexico
2025-04-01
Recruiting
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
NCT06635785Advanced Solid Tumor
OncoC4, Inc.
Phase 1/2
387
Alabama, Arkansas, District of Columbia, Florida, Illinois, Kentucky, Massachusetts, Michigan
2025-03-26
Active, closed
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
NCT06833008Advanced Solid Tumor
Ipsen
Phase 1/2
42
Michigan, Tennessee, Texas, Utah, Virginia
2025-03-14
Recruiting
ARC101 in Advanced Solid Tumors
NCT06672185Advanced Solid Tumor
Third Arc Bio
Phase 1
70
Massachusetts, Michigan, Texas
2025-02-05
Recruiting
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
NCT06750185Advanced Solid Tumor
BioNTech SE
Phase 1/2
248
Kentucky, Michigan, North Carolina, Rhode Island, South Carolina, Texas
2025-01-13
Active, closed
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors
DrugR-DXd
Daiichi Sankyo
Phase 2
335
Georgia, Michigan, New Jersey, New York, Tennessee, Texas
2025-01-06
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Cetuximab·Irinotecan
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Recruiting
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
NCT06352359Advanced Solid Tumor
OncoC4, Inc.
Phase 1
72
California, Florida, Kentucky, Michigan, Pennsylvania, Texas, Utah
2024-08-23
Active, closed
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NCT06577987Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer
Circle Pharma
Phase 1
220
Florida, Massachusetts, Michigan, Nevada, Ohio, Oregon, Tennessee, Texas
2024-08-14
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2024-07-01
Recruiting
Study of SGR-3515 In Participants With Advanced Solid Tumors.
NCT06463340Advanced Solid Tumor
Schrödinger, Inc.
Phase 1
52
Connecticut, Illinois, Michigan, New York, North Carolina, Ohio, Oklahoma, Tennessee
2024-06-18
Active, closed
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
NCT06480240Advanced Solid Tumor
OBI Pharma, Inc
Phase 1/2
117
California, Michigan, Texas, Virginia
2024-06-12
Active, closed
QTX3046 in Patients With KRAS G12D Mutations
NCT06428500Advanced Solid Tumor
Quanta Therapeutics
Phase 1
240
Michigan, North Carolina, Texas, Utah
2024-05-30
Active, closed
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer
Nuvation Bio Inc.
Phase 1/2
466
Michigan, New Jersey, New York, North Carolina, Texas, Utah, Virginia, Washington
2024-03-14
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
MacroGenics
Phase 1
250
California, Michigan, New York, Oregon, Texas, Utah
2024-03-06
Recruiting
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
NCT06241456Advanced Solid Tumor
DrugsFludara·Bendamustine·Cetuximab·Fludarabine
Fate Therapeutics
Phase 1
351
Arizona, California, Connecticut, Illinois, Michigan, Minnesota, Missouri, New York
2024-01-05
Recruiting
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
NCT06253130Advanced Solid Tumor
Eikon Therapeutics
Phase 1/2
156
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Michigan, Minnesota
2023-12-11
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Colorado, Florida, Michigan, North Carolina, Ohio, Tennessee, Texas
2023-12-01
Recruiting
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT05902988Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer
Volastra Therapeutics, Inc.
Phase 1/2
200
California, Colorado, Connecticut, Illinois, Indiana, Maryland, Michigan, New York
2023-10-18
Recruiting
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT05981703Advanced Solid Tumor, Solid Tumor
DrugTislelizumab
BeOne Medicines
Phase 1
337
California, Connecticut, Florida, Michigan, New Jersey, New York, Oregon, Texas
2023-09-21
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Florida, Georgia, Kansas, Michigan, New Jersey, New York, Oregon, Rhode Island
2023-08-18
Recruiting
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741Advanced Solid Tumor
DrugsDB-1310·Osimertinib·Trastuzumab·Capecitabine
DualityBio Inc.
Phase 1/2
1,000
California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Ohio, Tennessee
2023-08-17
Recruiting
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
NCT05898399Advanced Solid Tumor, Metastatic Solid Tumor
DrugOlaparib
Artios Pharma Ltd
Phase 1/2
181
Michigan, New York, Oklahoma, Pennsylvania, Tennessee, Texas
2023-06-30
Active, closed
Study of CHS-114 in Participants With Advanced Solid Tumors
NCT05635643Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
DrugsCHS-114·Toripalimab
Coherus Oncology, Inc.
Phase 1
87
California, Georgia, Kentucky, Maryland, Michigan, Missouri, Ohio, Tennessee
2022-12-15
Recruiting
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
NCT05768932Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
SillaJen, Inc.
Phase 1
260
Connecticut, Florida, Georgia, Michigan, New York, Oregon, Texas
2022-12-14
Active, closed
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
NCT05438329Advanced Solid Tumor
DrugsDB-1305/BNT325·Pumitamig
DualityBio Inc.
Phase 1/2
1,123
Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Michigan, Nevada
2022-07-19
Recruiting
A Study of YL201 in Patients With Advanced Solid Tumors
NCT05434234Advanced Solid Tumor
DrugTam-Peli
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
312
California, Colorado, District of Columbia, Massachusetts, Michigan, Missouri, New Mexico, New York
2022-05-25
Recruiting
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT05267626Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
DrugsAvelumab·Aldesleukin·Nivolumab
Aulos Bioscience, Inc.
Phase 1/2
159
Florida, Michigan, Minnesota, Missouri, North Carolina, Tennessee, Texas, Utah
2022-04-04
Active, closed
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05117476Advanced Solid Tumor, NSCLC
DrugsCLN-619·Carboplatin (AUC 6)·Dato-DXd·Pemetrexed
Cullinan Therapeutics Inc.
Phase 1
440
Alabama, California, Florida, Massachusetts, Michigan, New Jersey, New York, North Carolina
2021-10-29
Recruiting
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
DrugsKeytruda·Pembrolizumab
Medicenna Therapeutics, Inc.
Phase 1/2
115
California, Florida, Georgia, Michigan, Texas
2021-08-27
Recruiting
Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
NCT04855656Advanced Solid Tumor
DrugsCamonsertib·Lunresertib
Debiopharm International SA
Phase 1
464
California, Connecticut, Florida, Massachusetts, Michigan, Minnesota, Missouri, New York
2021-04-30
Recruiting
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
NCT04775485Low-grade Glioma, Advanced Solid Tumor
DrugTovorafenib
Day One Biopharmaceuticals, Inc.
Phase 2
141
California, District of Columbia, Illinois, Maryland, Massachusetts, Michigan, Missouri, New York
2021-04-22
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor
DrugsRezatapopt·Keytruda·Pembrolizumab
PMV Pharmaceuticals, Inc
Phase 1/2
300
California, Colorado, Connecticut, Delaware, Florida, Massachusetts, Michigan, New York
2020-10-29
Active, closed
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
NCT04592653Advanced Solid Tumor
DrugsKeytruda·Pembrolizumab
Mural Oncology, Inc
Phase 1/2
78
Michigan, Texas, Utah, Virginia
2020-09-30
Active, closed
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
NCT04145622Advanced Solid Tumor, Malignant Solid Tumor
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
247
Colorado, Florida, Massachusetts, Michigan, Missouri, New Jersey, New York, Tennessee
2019-11-03
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, New Jersey, New York
2019-09-18
Active, closed
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
NCT03993873Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
Turning Point Therapeutics, Inc.
Phase 1
95
California, Colorado, Illinois, Massachusetts, Michigan, Missouri, Ohio, Texas
2019-09-05
Rows per page Showing 1–43 of 43
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 October 2026. https://priyalifescience.com/clinical-trials-usa/state/michigan

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,122 studies in total at the last sync on 07 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 43 of those studies with a site in Michigan that also match the filters currently applied.

How many clinical trials are recruiting in Michigan?

30 of the 43 studies on this page are recruiting new participants as of the 07 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Michigan), 43 studies
PhaseStudiesRecruitingShare
Phase 1/2221651.2%
Phase 1191344.2%
Phase 2214.7%

Most active sponsors

Lead sponsors with the most studies (Michigan)
Lead sponsorStudiesRecruiting
Daiichi Sankyo31
MediLink Therapeutics (Suzhou) Co., Ltd.33
BeOne Medicines22
BioNTech SE22
Coherus Oncology, Inc.21
DualityBio Inc.21
Eli Lilly and Company21
Ipsen21
OncoC4, Inc.22
Artios Pharma Ltd11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.